Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5Z3VP)

• Drug Name: Ertumaxomab Drug Info
• Synonyms: Rexomab; Rexomun; Trifunctional antibody (breast cancer), TRION/Fresenius; Trifunctional bispecific (CD3/Her2/neu) antibody (breast cancer), TRION/Fresenius

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DM5Z3VP

Molecule-Related Drug Atlas

Drug(s) Targeting Erbb2 tyrosine kinase receptor (HER2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[2]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[3]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[4]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[5]
NERATINIB MALEATE	DMEDU7B	HER2/NEU overexpressing breast cancer	2C60-2C65	Approved	[6]
Margetuximab	DMKEY6S	HER2-positive breast cancer	2C60-2C65	Approved	[7]
Trastuzumab	DMZQOUX	Breast cancer	2C60-2C65	Approved	[8]
Tucatinib	DMBESUA	HER2-positive breast cancer	2C60-2C65	Approved	[9]
Pertuzumab	DMHJV0X	Adrenal gland neoplasm		Approved	[10]
Masoprocol	DMMVNZ0	Prostate cancer	2C82.0	Approved	[11]

Drug(s) Targeting T-cell surface glycoprotein CD3 gamma (CD3G)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tebentafusp	DMUJ1WV	Gastric cancer	2B72	Approved	[12]
Teplizumab	DMZ3P6C	Type-1 diabetes	5A10	Approved	[13]
MGD007	DMAHWLR	Colorectal cancer	2B91.Z	Phase 1/2	[14]
MT-110	DMPCUN5	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]
Autologous T-cell therapy	DMOAET3	Prostate cancer	2C82.0	Phase 1	[16]
MEDI-565	DMFWPLQ	Gastrointestinal cancer	2C11	Phase 1	[14]

Drug(s) Targeting T-cell surface glycoprotein CD3 epsilon (CD3E)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Muromonab	DM8ANCF	Organ transplant rejection	NE84	Approved	[17]
Resimmune	DMT5QSD	Cutaneous T-cell lymphoma	2B01	Phase 2	[18]
MT-110	DMPCUN5	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]
Autologous T-cell therapy	DMOAET3	Prostate cancer	2C82.0	Phase 1	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Erbb2 tyrosine kinase receptor (HER2)	TT6EO5L	ERBB2_HUMAN	Not Available	[1]
T-cell surface glycoprotein CD3 epsilon (CD3E)	TTZAT79	CD3E_HUMAN	Not Available	[1]
T-cell surface glycoprotein CD3 gamma (CD3G)	TTV3XPL	CD3G_HUMAN	Not Available	[1]

References

• [1] Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.
• [2] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
• [4] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [5] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [6] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [8] Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [10] Clinical pipeline report, company report or official report of Roche (2009).
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [15] EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74.
• [16] Antitumor activities of PSMA CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38.
• [17] Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs. 2003;63(24):2803-35.
• [18] Resimmune, an anti-CD3 recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.Haematologica.2015 Jun;100(6):794-800.